Table 2. Characteristics of studies exploring the relationship between CD147/EMMPRIN expression and tumor prognosis (Univariate model) V.
| Author | Year | Country | Cancer type | Stage/grade | Number | Age Median (range) | Follow-up time Median (range) | Detection method | Cut-off | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| Hai-Gang Li-42 | 2005 | China | Hepatocellular carcinoma | grade1–4 | 51 | 51 ± 11y (24–69y) | 26m (5–90m) | IHC | ≥10% | DFS |
| Wen-Chiuan Tsai -43 | 2006 | China | Renal cell carcinoma | I–IV | 100 | NA | 5–year | TMA/IHC | score > 130 | OS |
| Nobuyuki Hakuma-44 | 2007 | Japan | Non-Small Cell Lung Cancers | stage I | 95 | 62.8 ± 9.1 | 5–y | IHC | score > 3 | OS |
| Wen Chiuan Tsai-45 | 2007 | China | Pancreatobiliary adenocarcinoma | T4 | 70 | NA | 2–y | IHC | score > 100 | OS |
| Wei Wu-46 | 2008 | China | Gallbladder carcinoma | I–IV | 108 | 51.63 ± 10.08y (35–76y) | 5–9y | IHC | ≥5% | OS |
| Daniel Buergy-47 | 2009 | Germany | Colorectal Cancer | I–IV | 40 | NA | 30 months | IHC | ≥5% | DSS |
| Ziming Du-48 | 2009 | China | Nasopharyngeal carcinoma | I–IV | 157 | 46y (14–86y) | 5–y | TMA/IHC | ≥5% | OS |
| Zhaodong Han-49 | 2010 | China | Renal/Bladder/Prostate carcinoma | I–IV | 52/58/101 | 57.26 ± 11.2y | 1–5y | IHC | ≥5% | OS |
| H. Z. Zeng-7 | 2011 | China | Non-small-cell lung cancer | III/IV | 118 | NA | NA | IHC | ≥25% | OS |
| Congfa Huang-9 | 2012 | China | Tongue squamous cell carcinoma | I–IV | 80 | NA | 69m (2–106m) | IHC | ≥10% | OS |
| Larissa Sweeny-50 | 2012 | USA | Cutaneous Squamous Cell Carcinoma | III–IV | 56 | 72 ± 12 (42–91) | >2y | IHC | ≥25% | OS |
| Keiichiro Nakamura-51 | 2012 | Japan | Endometrial cancer | I–IV | 134 | 57.7y (28–85) | NA | IHC | ≥10% | DFS, OS |
| Mototaka Sato-52 | 2013 | Japan | Renal cell carcinoma | I–IV | 50 | 27–82 (62) | 52 (1–114 m) | IHC | score ≥ 1 | OS, PFS |
| Wen Chiuan Tsai-53 | 2013 | China | Astrocytomas | III–IV | 77 | NA | NA | GDS1962 database | 1,500 | OS |
| Qing Yang-54 | 2013 | China | Hypopharyngeal Squamous Cell Carcinoma | I–IV | 80 | 60.73y (42–78) | IHC | ≥P90 level | RFS | |
| Xinwen Zhong-55 | 2013 | China | Lung cancer | T1 | 180 | 60y (37–75y) | 60m (3–96m) | IHC | ≥25% | OS |
| Jung-Woo Choi-56 | 2014 | Korea | Urothelial carcinoma of the bladder | Ta–T4 | 360 | 69y (23–97y) | 36m | TMA/IHC | score > 16 | OS |
| Xin-Qiong Huang-57 | 2014 | China | Cervical squamous cell carcinoma | IB-IVA | 132 | 51y (28–80y) | 45m (2–85.5m) | IHC | ≥5% | PFS |
| Céline Pinheiro-58 | 2014 | Portugal | Soft tissue sarcomas | I–III | 84 | NA | NA | IHC | score ≥ 3 | OS |
| Younghye Kim-59 | 2015 | Korea | Clear cell renal cell carcinoma | I–IV | 180 | 25–83y (58y) | 40.7m (1–173) | TMA/IHC | score > 17 | PFS |